Matsuzawa-Ishimoto, Yu
Yao, Xiaomin
Koide, Akiko
Ueberheide, Beatrix M.
Axelrad, Jordan E. http://orcid.org/0000-0003-1951-7790
Reis, Bernardo S. http://orcid.org/0000-0002-6841-116X
Parsa, Roham
Neil, Jessica A. http://orcid.org/0000-0003-2824-3701
Devlin, Joseph C.
Rudensky, Eugene
Dewan, M. Zahidunnabi
Cammer, Michael http://orcid.org/0000-0003-4930-1739
Blumberg, Richard S. http://orcid.org/0000-0002-9704-248X
Ding, Yi
Ruggles, Kelly V. http://orcid.org/0000-0002-0152-0863
Mucida, Daniel http://orcid.org/0000-0002-0000-0452
Koide, Shohei http://orcid.org/0000-0001-5473-4358
Cadwell, Ken http://orcid.org/0000-0002-5860-0661
Article History
Received: 29 October 2021
Accepted: 22 August 2022
First Online: 5 October 2022
Competing interests
: K.C. has received research support from Pfizer, Takeda, Pacific Biosciences, Genentech and Abbvie. K.C. has consulted for or received honoraria from Puretech Health, Genentech, Abbvie, GentiBio and Synedgen. K.C. is an inventor on US patent 10,722,600 and provisional patent 62/935,035, and K.C., S.K., A.K. and Y.M.-I. are inventors on US patent 63/157,225. S.K. was a scientific advisory borard member of, held equity in and received consulting fees from Black Diamond Therapeutics, has received research support from Argenx BVBA, Black Diamond Therapeutics and Puretech Health and is a co-founder of Revalia Bio.